Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRV Platform of Localized Nanoengineered Therapies for Oral Cavity and Lung Cancers
NCT05893888Phase 3Recruiting
- Sponsor
- Privo Technologies, Inc.
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 3, open-label trial of PRV111, cisplatin nano-engineered intraoperative system and PRV131 in oral squamous cell carcinoma (OSCC), lung cancer and carcinoma in situ (CIS) (4 arms), sponsored by Privo Technologies, Inc. Primary endpoints: Overall Response Rate and Safety assessed via dose-limiting toxicities. Started Nov 2024; status: recruiting.
02
Drugs
PRV111cisplatin nano-engineered intraoperative systemPRV131
03
Conditions
oral squamous cell carcinoma (OSCC)lung cancercarcinoma in situ (CIS)
Beyond the preview
Go deeper on NCT05893888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893888.